About 31 results found for searched term "Ac9-25" (0.095 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M7619 | AC-93253 iodide | Others |
| AC-93253 is a potent, cell permeable, subtype selective RAR (RARα) agonist. | ||
| M54382 | Ac9-25 | FPR |
| Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR. | ||
| M2104 | BYL-719 | PI3K |
| Alpelisib; BYL719 | ||
| Alpelisib (Byl-719) is an effective, selective PI3Kα inhibitor with oral activity. Alpelisib (Byl-719) was targeted to PIK3CA mutated carcinoma. The IC50 of Alpelisib (Byl-719) against P110 α, P110 γ, p110δ and P110 β were 5 nM, 250 nM, 290 nM and 1200 nM, respectively. It has antitumor activity. | ||
| M2192 | BMS-754807 | IGF-1R |
| Bms-754807 is a potent igf-1r /InsR reversible inhibitor with an IC50 of 1.8 nM/1.7 nM and also inhibits the activity of Met, RON, TrkA, TrkB, AurA and AurB with an IC50 value of 6,44,7,4, respectively. At 9 and 25 nM, it has almost no inhibitory activity against Flt3, Lck, MK2, PKA and PKC. | ||
| M3975 | Lorlatinib (PF-06463922) | ALK |
| PF-06463922 | ||
| Lorlatinib (PF-06463922) is an oral active, selective, brain osmotic and ATP-competitive ROS1/ALK inhibitor. The Ki of Lorlatinib for ROS1, wild-type ALK and ALK(L1196M) were <0.025 nM, <0.07 nM and 0.7 nM, respectively. Lorlatinib has anticancer activity. | ||
| M5046 | Imidafenacin (ONO-8025) | AChR/AChE |
| KRP-197; ONO-8025 | ||
| Imidafenacin (ONO-8025) is a urinary antispasmodic of the anticholinergic class.Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors (IC50=4.13 nM). | ||
| M6070 | EDO-S101 | HDAC |
| Tinostamustine; EDO-S-101; EDO-S 101 | ||
| EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively. | ||
| M6649 | CZC-25146 | LRRK2 |
| CZC25146 | ||
| CZC 25146 is a potent and orally active LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. | ||
| M8090 | PF-04965842 | JAK |
| Abrocitinib | ||
| Abrocitinib is an orally active and selective JAK1 inhibitor with an IC50 value of 29 nM. Abrocitinib reversibly inhibits JAK1 kinase by blocking its ATP-binding site. Abrocitinib (PF-04965842) inhibited TYK2 activity (IC50, 1.253 μM) and phosphorylation of STAT1, STAT3, and STAT5 after stimulation. It can be used in the study of autoimmune diseases. | ||
| M10709 | TAS0728 | EGFR/HER2 |
| TAS0728 is an effective, selective, oral, irreversible, covalently bound HER2 inhibitor covalently bound to the C805 site of HER2, inhibiting its activity.IC50 The value is 13 nM. TAS0728 to BMX, HER4, BLK, EGFR, JAK3, SLK, LOK and HUMAN HER2 IC50 The values are 4.9, 8.5, 31, 65, 33, 25, 86, and 36 nM, respectively. TAS0728 simultaneously inhibits phosphorylation of HER2, HER3 and its downstream effector proteins. Has antitumor activity. | ||
| M11041 | WEHI-9625 | VDAC |
| WEHI-9625 is a first-in-class tricyclic sulfone, first-in-class inhibitor of apoptosis with an EC50 of 69 nM. WEHI-9625 binds to VDAC2 and promotes its ability to inhibit apoptosis driven by mouse BAK. WEHI-9625 is completely inactive against both human BAK and the closely related apoptosis effector BAX. | ||
| M11264 | KI-7 | Adenosine Receptor |
| Ki-7 is an A2B adenosine receptor positive allosteric regulator. Ki-7 enhances cAMP accumulation induced by NECA, a non-selective A2B adenosine receptor agonist (EC50=445.8 nM). Ki-7 also enhanced selective A2B adenosine receptor agonist BAY 60-6583 and adenosine-induced cAMP accumulation with EC50 of 2390 nM and 2550 nM, respectively. | ||
| M11473 | BAY 2666605 | Others |
| BAY 2666605 is an oral active PDE3A and PDE3B inhibitor with IC50 of 87 nM and 50 nM, respectively. BAY 2666605 is a pDE3A-SLFN12 compound inducer (WO2019025562A1; Example, 135). | ||
| M11496 | FGF-basic, Rat (E. coli) | Recombinant Proteins |
| Fibroblast Growth Factor-basic; FGF-2; BFGF; FGFB; HBGF-2; bFGF; Prostatropin | ||
| FGF-basic, Rat（E. coli） Expressed with an n-terminal Gly. FGF-basic (Pro10-Ser154) Accession # P13109. Bioactivity: ED50 < 0.25 ng/ mL, measured by 3T3 cell proliferation method, corresponding to > 4.0 × 106 units /mg. | ||
| M13908 | AVE 0991 sodium salt | Angiotensin Receptor |
| AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM. | ||
| M14871 | Gefitinib-based PROTAC 3 | PROTAC |
| Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a von Hippel-Lindau ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively. | ||
| M15079 | Recombinant Human NT-3 (E.coli) | Recombinant Proteins |
| Neurotrophin-3; NT-3; HDNF; Nerve Growth Factor 2 | ||
| Recombinant human neurotrophic factor-3 was prepared by escherichia coli expression system and the target gene encoding Tyr139-Thr257 was expressed. Accession # : P20783. | ||
| M20606 | SAR125844 | c-Met |
| SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively). | ||
| M20833 | Vodobatinib (K0706) | Src-bcr-Abl |
| SCO-088, SUN K706, SUN-K0706 | ||
| Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively. | ||
| M21335 | Fluo-5N,AM | Fluorescent Dye |
| Calcium fluorescent probe Fluo-5N,AM is a calcium fluorescent probe, Fluo-5N is an analog of Fluo-4 with a low calcium binding affinity (Kd = ~90 uM), making it suitable for detecting intracellular calcium levels in the range of 1 μM to 1 mM, which would saturate the Fluo-4 response. The optimal excitation/emission wavelength is 490 nm/525 nm. | ||
| M21550 | Recombinant Mouse/Rat TGF-beta 1 (Mammalian) | Recombinant Proteins |
| TGFB; TGF-b1; TGFB1; CEDLAP;latency-associated peptide | ||
| Recombinant mouse/rat transforming growth factor β1 is produced by the mammalian expression system and the target gene encoding Ala279-Ser390 is expressed. Measured by its ability to inhibit IL-4-dependent proliferation of TF‑1 human erythroleukemic cells.The ED50 for this effect is 5-25 pg/ml. | ||
| M25497 | (Rac)-BIO8898 | TNF Receptor |
| (Rac)-BIO8898 is a CD40-CD154 co-stimulatory interaction inhibitor. (Rac)-BIO8898 inhibits CD154 binding to CD40-Ig with an IC50 of 25 μM. | ||
| M27630 | Azvudine | Reverse Transcriptase |
| RO-0622; FNC | ||
| Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). Azvudine inhibits NRTI-resistant viral strains. | ||
| M27775 | BS-194 | CDK |
| BS-194 is an orally active, selective and potent CDK inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC50s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer. | ||
| M27856 | Lanopepden | Antibiotic |
| GSK 1322322 | ||
| Lanopepden (GSK 1322322) is a peptide deformylase inhibitor active against Staphylococcus aureus strains with MICs of 1 and 1 mg/L for ATCC 29213 and ATCC 25923 strain, respectively. | ||
| M27865 | Histatin 5 | MMP |
| Histatin 5 inhibits the activity of the host matrix metalloproteinases MMP-2 and MMP-9 with IC50s of 0.57 and 0.25 μM, respectively. | ||
| M27954 | CBK289001 | PAR |
| CBK289001 is a tartrate-resistant acid phosphatase (TRAP/ACP5) inhibitor. CBK289001 inhibits TRAP 5bMV, TRAP 5bOX and TRAP 5aOX with IC50s of 125 µM, 4.21 µM and 14.2 µM, respectively. | ||
| M28134 | Sampatrilat | ACE |
| UK-81252 | ||
| Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation. | ||
| M28185 | Azvudine hydrochloride | Reverse Transcriptase |
| RO-0622 hydrochloride; FNC hydrochloride | ||
| Azvudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine hydrochloride exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride inhibits NRTI-resistant viral strains. | ||
| M28208 | Naldemedine tosylate | Opioid Receptor |
| S-297995 tosylate | ||
| Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. | ||
| M28352 | BRD6688 | HDAC |
| BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
